On behalf of MiECTiS Executive Board we invite you at a MiECS Update Zoom Meeting on Monday 4th November 2024 at 17:00-18:30 CET. The aim of the Meeting is to liaise all centres that implement MiECC in clinical practice with MiECS Steering Committee so as to facilitate recruitment in participating ones and promote it to others that may be interested in joining the study. 
The link is:
Join Zoom Meeting
https://authgr.zoom.us/j/99758132943?pwd=RkJrWmptVDFjbzdzMzdpY3NHSW1aQT09
Meeting ID: 997 5813 2943
Passcode: 783084
MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted by Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the serious perfusion-related postoperative morbidity. The study is led by the Clinical Research Unit of the Biomedical Research and Education Special Unit (BRESU), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board Member of MiECTiS.
MiECS follows COMICS study on the topic which was prematurely terminated due to the pandemic situation. COMICS found in 1,071 patients a significant reduction in the risk of serious adverse events favouring MiECC as well as improvement in quality-of-life. MiECS is adequately powered to influence clinical practice, and it is designed to overcome all perceived limitations of previous trials. The aim is to provide a definite answer on whether MiECC use should be regarded as the optimal perfusion strategy in cardiac surgery.
The study is currently conducted in 6 cardiac centres worldwide with approximately 200 recruited patients so far. More than 15 cardiac surgery centres (Germany, Greece, Italy, United Kingdom, Switzerland, Turkey and Canada) have been invited to participate. The trial is powered by Dendrite Clinical Systems’, a global leader in cardiac surgical registries.